The newly approved drug provides a new, single-tablet treatment option, taken twice-daily, for patients who need to control their blood sugar.
Jentadueto is a prescription medication used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate, the Eli Lilly said.
At the maximum dose, Jentadueto demonstrated placebo-corrected reductions in hemoglobin A(1c) (HbA(1c) or A1C) levels of up to 1.7% (+0.1% for placebo and -1.6% for JJentadueto ).
Jentadueto can be used alone or in combination with a sulfonylurea, a commonly prescribed medication for type 2 diabetes.
Linagliptin (5mg, once-daily) is marketed as Tradjenta (linagliptin) tablets in the US.